View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 4, 2020updated 12 Jul 2022 11:48am

UK researchers launch trial of blood plasma therapy for Covid-19

Researchers at Guy's and St Thomas' NHS Foundation Trust in the UK have launched a clinical trial to assess blood plasma therapy for Covid-19 treatment.

Researchers at Guy’s and St Thomas’ NHS Foundation Trust in the UK have launched a clinical trial to assess blood plasma therapy for Covid-19 treatment.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Guy’s and St Thomas’ is one of the first sites participating in the REMAP-CAP trial, which is assessing various therapies for severely ill patients.

The plasma therapy, called convalescent plasma treatment, requires blood plasma donations from people who have recovered from Covid-19.

This plasma is administered to Covid-19 patients who could not generate sufficient antibodies against the virus.

Guy’s and St Thomas’ clinician scientist Dr Manu Shankar-Hari said: “At the moment, there is no proven treatment for Covid-19.

“Convalescent plasma is a promising treatment that could help patients whose bodies aren’t producing enough antibodies to curb the disease. This trial will help us understand whether the treatment should be used more widely to treat Covid-19.”

With support from UK National Institute for Health Research (NIHR), the trial is co-led by Dr Shankar-Hari with NHS Blood and Transplant and University of Cambridge experts.

Last month, the UK Government approved a national clinical trial to assess plasma therapy for the treatment of Covid-19 patients.

The trial will assess the effectiveness of convalescent plasma, which is obtained from recovered patients, in severely ill Covid-19 patients.

A scaled-up national programme, if effective, will supply up to 10,000 units of convalescent plasma each week to the NHS, enabling the treatment of 5,000 patients per week.

Researchers will use plasma from patients who have recovered for at least 28 days to ensure increased antibody levels.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena